Stock REPL REPLIMUNE GROUP, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Replimune Group, Inc.

Equities

REPL

US76029N1063

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-25 EDT 		5-day change 1st Jan Change
8.82 USD +0.68% Intraday chart for Replimune Group, Inc. +15.45% +4.63%
06-24 Replimune Group, Inc.(NasdaqGS:REPL) dropped from S&P Biotechnology Select Industry Index CI
06-13 Replimune Group Signs $100 Million PIPE Deal with Institutional Investors MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Replimune Group, Inc.(NasdaqGS:REPL) dropped from S&P Biotechnology Select Industry Index
CI
Replimune Group Signs $100 Million PIPE Deal with Institutional Investors
MT
Replimune Announces $100 Million Private Placement Financing
AQ
Replimune : Corporate Presentation June 2024
PU
Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding
CI
HC Wainwright Adjusts Price Target on Replimune to $17 From $12, Maintains Buy Rating
MT
Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
AQ
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
MT
Sector Update: Health Care
MT
Replimune Shares Rise as Study Data on Melanoma Treatment Improves
MT
Replimune : Primary Analysis of the IGNYTE Registrational Cohort Presentation June 2024
PU
Transcript : Replimune Group, Inc. - Special Call
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
AQ
Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma
CI
Replimune : IGNYTE Oral Presentation at ASCO 2024
PU
Replimune : RP2 Uveal Melanoma Oral Presentation at ASCO 2024
PU
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology Annual Meeting
CI
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. REPL Stock
  4. News Replimune Group, Inc.